New agents in acute myeloid leukemia (AML)

Silvia PARK; Byung-Sik CHO; Hee-Je KIM.
Blood Research ; : S14-S18, 2020.
Artículo | WPRIM | ID: wpr-830986

Documentos relacionados

  1. New agents in acute myeloid leukemia (AML).
  2. Therapies for acute myeloid leukemia in patients ineligible for standard induction chemotherapy: a systematic review.
  3. A User's Guide to Novel Therapies for Acute Myeloid Leukemia.
  4. CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia.
  5. New Treatment Options for Older Patients with Acute Myeloid Leukemia.
  6. The increasingly blurred line between induction, consolidation and maintenance in acute myeloid leukaemia.
  7. Astaxanthin decreases the growth-inhibitory dose of cytarabine and inflammatory response in the acute lymphoblastic leukemia cell line NALM-6.
  8. Subclones of bone marrow CD34<sup>+</sup> cells in acute myeloid leukemia at diagnosis confer responses of patients to induction chemotherapy.
  9. [Incorporation of novel agents into the treatment for acute myeloid leukemia].
  10. Combination strategies to promote sensitivity to cytarabine-induced replication stress in acute myeloid leukemia with and without DNMT3A mutations.